“Real-Time” High-Throughput Drug and Synergy Testing for Multidrug-Resistant Bacterial Infection: A Case Report

Antibiotic management of infections with multidrug-resistant organisms (MDRO) represents a complex clinical challenge. We report here the first patient with a severe MDRO infection managed with assistance of a novel “real-time” 3-day high-throughput screen (HTS) that allowed screening of 9 drugs in...

Full description

Bibliographic Details
Main Authors: Wei Sun, Shayla Hesse, Miao Xu, Richard W. Childs, Wei Zheng, Peter R. Williamson
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-09-01
Series:Frontiers in Medicine
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fmed.2018.00267/full
id doaj-ee63eb18bade46dab7fac03f184271fa
record_format Article
spelling doaj-ee63eb18bade46dab7fac03f184271fa2020-11-24T21:26:10ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2018-09-01510.3389/fmed.2018.00267412539“Real-Time” High-Throughput Drug and Synergy Testing for Multidrug-Resistant Bacterial Infection: A Case ReportWei Sun0Shayla Hesse1Miao Xu2Richard W. Childs3Wei Zheng4Peter R. Williamson5National Center for Advancing Translational Sciences, Bethesda, MD, United StatesLaboratory of Molecular Biology, National Cancer Institute, Bethesda, MD, United StatesNational Center for Advancing Translational Sciences, Bethesda, MD, United StatesTransplantation Immunotherapy, Hematology Branch, National Heart Lung and Blood Institute, Bethesda, MD, United StatesNational Center for Advancing Translational Sciences, Bethesda, MD, United StatesLaboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United StatesAntibiotic management of infections with multidrug-resistant organisms (MDRO) represents a complex clinical challenge. We report here the first patient with a severe MDRO infection managed with assistance of a novel “real-time” 3-day high-throughput screen (HTS) that allowed screening of 9 drugs in 14 combinations in 2,304 total samplings. Identified synergies were used to modify patient therapy with the goal of reducing drug-induced toxicity. The desired clinical outcome was achieved on the HTS-informed therapeutic regimen, supporting the utility of HTS technology to expand standard antimicrobial susceptibility testing.https://www.frontiersin.org/article/10.3389/fmed.2018.00267/fullmultidrug-resistant organismsKlebsiella pneumoniaereal-time drug testantibiotic combination therapydrug repurposing screen
collection DOAJ
language English
format Article
sources DOAJ
author Wei Sun
Shayla Hesse
Miao Xu
Richard W. Childs
Wei Zheng
Peter R. Williamson
spellingShingle Wei Sun
Shayla Hesse
Miao Xu
Richard W. Childs
Wei Zheng
Peter R. Williamson
“Real-Time” High-Throughput Drug and Synergy Testing for Multidrug-Resistant Bacterial Infection: A Case Report
Frontiers in Medicine
multidrug-resistant organisms
Klebsiella pneumoniae
real-time drug test
antibiotic combination therapy
drug repurposing screen
author_facet Wei Sun
Shayla Hesse
Miao Xu
Richard W. Childs
Wei Zheng
Peter R. Williamson
author_sort Wei Sun
title “Real-Time” High-Throughput Drug and Synergy Testing for Multidrug-Resistant Bacterial Infection: A Case Report
title_short “Real-Time” High-Throughput Drug and Synergy Testing for Multidrug-Resistant Bacterial Infection: A Case Report
title_full “Real-Time” High-Throughput Drug and Synergy Testing for Multidrug-Resistant Bacterial Infection: A Case Report
title_fullStr “Real-Time” High-Throughput Drug and Synergy Testing for Multidrug-Resistant Bacterial Infection: A Case Report
title_full_unstemmed “Real-Time” High-Throughput Drug and Synergy Testing for Multidrug-Resistant Bacterial Infection: A Case Report
title_sort “real-time” high-throughput drug and synergy testing for multidrug-resistant bacterial infection: a case report
publisher Frontiers Media S.A.
series Frontiers in Medicine
issn 2296-858X
publishDate 2018-09-01
description Antibiotic management of infections with multidrug-resistant organisms (MDRO) represents a complex clinical challenge. We report here the first patient with a severe MDRO infection managed with assistance of a novel “real-time” 3-day high-throughput screen (HTS) that allowed screening of 9 drugs in 14 combinations in 2,304 total samplings. Identified synergies were used to modify patient therapy with the goal of reducing drug-induced toxicity. The desired clinical outcome was achieved on the HTS-informed therapeutic regimen, supporting the utility of HTS technology to expand standard antimicrobial susceptibility testing.
topic multidrug-resistant organisms
Klebsiella pneumoniae
real-time drug test
antibiotic combination therapy
drug repurposing screen
url https://www.frontiersin.org/article/10.3389/fmed.2018.00267/full
work_keys_str_mv AT weisun realtimehighthroughputdrugandsynergytestingformultidrugresistantbacterialinfectionacasereport
AT shaylahesse realtimehighthroughputdrugandsynergytestingformultidrugresistantbacterialinfectionacasereport
AT miaoxu realtimehighthroughputdrugandsynergytestingformultidrugresistantbacterialinfectionacasereport
AT richardwchilds realtimehighthroughputdrugandsynergytestingformultidrugresistantbacterialinfectionacasereport
AT weizheng realtimehighthroughputdrugandsynergytestingformultidrugresistantbacterialinfectionacasereport
AT peterrwilliamson realtimehighthroughputdrugandsynergytestingformultidrugresistantbacterialinfectionacasereport
_version_ 1725980595039764480